FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053222703> ?p ?o ?g. }

• W2053222703 endingPage "863" @default.
• W2053222703 startingPage "858" @default.
• W2053222703 abstract "Background. ISIS 2302, an antisense oligonucleotide that inhibits the expression of human intercellular adhesion molecule (ICAM)-1, was evaluated in combination with a cyclosporine (CsA)-prednisone (Pred) regimen first in a phase I safety and pharmacokinetic study and then in a phase II assessment of prophylaxis of acute rejection episodes in deceased donor renal allografts. Methods. Both phase I and phase II trials were double-blinded and placebo-controlled, including 17 stable and 39 de novo patients, respectively, in time-lagged, ascending-dose regimens. Each study compared the outcomes of 8 alternate-day intravenous infusions of four ISIS 2302 dose levels (0.05, 0.5, 1.0, or 2.0 mg/kg) versus placebo (3:1 ratio). Patients were followed for 34 days (phase I) or 6 months (phase II). All transplant patients were followed for 3 years. Results. ISIS 2302 produced no evident toxicity; a significant, dose-related increase in activated partial thromboplastin time was accompanied by a trend toward a decreased platelet count. ISIS 2302 did not alter the pharmacokinetic behavior of CsA. At 6 months, the rates of acute rejection episodes were 38.1% in the ISIS 2302 group versus 20.0% in the placebo group. Three-year graft survivals were similar. The mean creatinine values at 1, 2, and 3 years for all ISIS dose groups combined versus placebo over 3 years showed no significant differences. Conclusions. ISIS 2302 did not evoke side-effects and produced slightly improved renal function. However, in this pilot study, it did not further reduce the rate of acute rejection episodes or increase graft survival compared to a concentration-controlled CsA-Pred regimen." @default.
• W2053222703 created "2016-06-24" @default.
• W2053222703 creator A5002331967 @default.
• W2053222703 creator A5011704380 @default.
• W2053222703 creator A5016800140 @default.
• W2053222703 creator A5019700729 @default.
• W2053222703 creator A5027596271 @default.
• W2053222703 creator A5046113166 @default.
• W2053222703 creator A5051083446 @default.
• W2053222703 creator A5051771284 @default.
• W2053222703 date "2004-09-27" @default.
• W2053222703 modified "2023-09-26" @default.
• W2053222703 title "Phase I and Phase II Safety and Efficacy Trial of Intercellular Adhesion Molecule-1 Antisense Oligodeoxynucleotide (ISIS 2302) for the Prevention of Acute Allograft Rejection" @default.
• W2053222703 cites W1824700770 @default.
• W2053222703 cites W1970650788 @default.
• W2053222703 cites W1981801952 @default.
• W2053222703 cites W2011779487 @default.
• W2053222703 cites W2028146382 @default.
• W2053222703 cites W2036801946 @default.
• W2053222703 cites W2041658049 @default.
• W2053222703 cites W2058165751 @default.
• W2053222703 cites W2072201785 @default.
• W2053222703 cites W2089467047 @default.
• W2053222703 cites W2089629205 @default.
• W2053222703 cites W2122980035 @default.
• W2053222703 cites W2126925126 @default.
• W2053222703 cites W2320948705 @default.
• W2053222703 doi "https://doi.org/10.1097/01.tp.0000128857.77893.d2" @default.
• W2053222703 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15385805" @default.
• W2053222703 hasPublicationYear "2004" @default.
• W2053222703 type Work @default.
• W2053222703 sameAs 2053222703 @default.
• W2053222703 citedByCount "30" @default.
• W2053222703 countsByYear W20532227032012 @default.
• W2053222703 countsByYear W20532227032013 @default.
• W2053222703 countsByYear W20532227032014 @default.
• W2053222703 countsByYear W20532227032016 @default.
• W2053222703 countsByYear W20532227032017 @default.
• W2053222703 countsByYear W20532227032019 @default.
• W2053222703 countsByYear W20532227032021 @default.
• W2053222703 countsByYear W20532227032022 @default.
• W2053222703 crossrefType "journal-article" @default.
• W2053222703 hasAuthorship W2053222703A5002331967 @default.
• W2053222703 hasAuthorship W2053222703A5011704380 @default.
• W2053222703 hasAuthorship W2053222703A5016800140 @default.
• W2053222703 hasAuthorship W2053222703A5019700729 @default.
• W2053222703 hasAuthorship W2053222703A5027596271 @default.
• W2053222703 hasAuthorship W2053222703A5046113166 @default.
• W2053222703 hasAuthorship W2053222703A5051083446 @default.
• W2053222703 hasAuthorship W2053222703A5051771284 @default.
• W2053222703 hasBestOaLocation W20532227031 @default.
• W2053222703 hasConcept C112705442 @default.
• W2053222703 hasConcept C126322002 @default.
• W2053222703 hasConcept C126894567 @default.
• W2053222703 hasConcept C141071460 @default.
• W2053222703 hasConcept C142724271 @default.
• W2053222703 hasConcept C147483822 @default.
• W2053222703 hasConcept C159641895 @default.
• W2053222703 hasConcept C203014093 @default.
• W2053222703 hasConcept C204787440 @default.
• W2053222703 hasConcept C27081682 @default.
• W2053222703 hasConcept C2776914184 @default.
• W2053222703 hasConcept C2778261982 @default.
• W2053222703 hasConcept C2780306776 @default.
• W2053222703 hasConcept C2780868878 @default.
• W2053222703 hasConcept C2781413609 @default.
• W2053222703 hasConcept C2909375385 @default.
• W2053222703 hasConcept C71924100 @default.
• W2053222703 hasConcept C89560881 @default.
• W2053222703 hasConcept C90924648 @default.
• W2053222703 hasConcept C98274493 @default.
• W2053222703 hasConceptScore W2053222703C112705442 @default.
• W2053222703 hasConceptScore W2053222703C126322002 @default.
• W2053222703 hasConceptScore W2053222703C126894567 @default.
• W2053222703 hasConceptScore W2053222703C141071460 @default.
• W2053222703 hasConceptScore W2053222703C142724271 @default.
• W2053222703 hasConceptScore W2053222703C147483822 @default.
• W2053222703 hasConceptScore W2053222703C159641895 @default.
• W2053222703 hasConceptScore W2053222703C203014093 @default.
• W2053222703 hasConceptScore W2053222703C204787440 @default.
• W2053222703 hasConceptScore W2053222703C27081682 @default.
• W2053222703 hasConceptScore W2053222703C2776914184 @default.
• W2053222703 hasConceptScore W2053222703C2778261982 @default.
• W2053222703 hasConceptScore W2053222703C2780306776 @default.
• W2053222703 hasConceptScore W2053222703C2780868878 @default.
• W2053222703 hasConceptScore W2053222703C2781413609 @default.
• W2053222703 hasConceptScore W2053222703C2909375385 @default.
• W2053222703 hasConceptScore W2053222703C71924100 @default.
• W2053222703 hasConceptScore W2053222703C89560881 @default.
• W2053222703 hasConceptScore W2053222703C90924648 @default.
• W2053222703 hasConceptScore W2053222703C98274493 @default.
• W2053222703 hasIssue "6" @default.
• W2053222703 hasLocation W20532227031 @default.
• W2053222703 hasLocation W20532227032 @default.
• W2053222703 hasLocation W20532227033 @default.
• W2053222703 hasOpenAccess W2053222703 @default.
• W2053222703 hasPrimaryLocation W20532227031 @default.
• W2053222703 hasRelatedWork W1544023406 @default.

• next